# Fondaparinux

Drug · id `cardio:fondaparinux` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Arixtra; Fondaparinux sodium

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

Fondaparinux, sold as Arixtra, is an anticoagulant of the Factor Xa inhibitor type, given by injection under the skin. The US label read lists, in adults, prophylaxis of deep vein thrombosis in people having hip fracture, hip replacement, knee replacement or abdominal surgery, and treatment of acute deep vein thrombosis or acute pulmonary embolism when given with warfarin sodium. It also lists treatment of venous thromboembolism in children aged 1 year or older who weigh at least 10 kg. The label carries a boxed warning about epidural or spinal hematomas in people who are anticoagulated and have neuraxial anesthesia or a spinal puncture.

## Technical summary

RxNorm ingredient 321208; UNII X0Q6N9USOZ is the UNII of fondaparinux sodium, the form the label names, and is a broad match. MeSH descriptor D000077425 is Fondaparinux. Class: Factor Xa Inhibitor (FDA established pharmacologic class, RxClass); the label also writes (anticoagulant) after the class name. The label read is the Mylan Institutional LLC label for Arixtra, application NDA021345, effective 2024-12-10 in openFDA. Adult and paediatric statements are kept in separate contexts and claims. This page records label indications, the first sentence of the boxed warning and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Children for whom the US label of fondaparinux (Arixtra) lists an indication: venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg

Recipient: Child; Population: Pediatric patients aged 1 year or older who weigh at least 10 kg, as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Children aged 1 year or older, as the passage read states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, lists the medicine for the treatment of venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Pediatric patients aged 1 year or older who weigh at least 10 kg, as the label states.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Children aged 1 year or older, as the passage read states; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label's paediatric use, dosing and safety sections were not read. The adult indications are recorded in a separate claim. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective\_time). Generic fondaparinux labels in openFDA were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.4 Treatment of Venous Thromboembolism in Pediatric Patients. Retrieved 2026-11-09T13:16:13Z. Source state: Current. Version fingerprint: 1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9.
     How it applies: Label passage quoted in the research quote table (LB-07).
  2. Background: openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective\_time). Generic fondaparinux labels in openFDA were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:16:13Z. Source state: Current. Version fingerprint: 1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9.
     How it applies: Effective date of the label text read, 20241210.

## Context: Adults for whom the US label of fondaparinux (Arixtra) lists an indication: prophylaxis of deep vein thrombosis after hip fracture, hip replacement, knee replacement or abdominal surgery; treatment of deep vein thrombosis or acute pulmonary embolism

Recipient: Adult; Population: Adult patients described in the indications sections of the label.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the passages read state; Follow-up: Not applicable (label statement)

### The US label of Arixtra (fondaparinux sodium), in the Mylan Institutional LLC version dated 2024-12-10 in openFDA, describes fondaparinux as a Factor Xa inhibitor (anticoagulant) and lists it, in adult patients, for the prophylaxis of deep vein thrombosis in patients undergoing hip fracture surgery, hip replacement surgery, knee replacement surgery or abdominal surgery, and for the treatment of deep vein thrombosis or acute pulmonary embolism when administered in conjunction with warfarin sodium. The label carries a boxed warning about epidural or spinal hematomas in anticoagulated patients who receive neuraxial anesthesia or undergo spinal puncture.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adult patients described in the indications sections of the label.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the passages read state; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for in adults. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The paediatric indication is recorded in a separate claim. Only the indications, the first sentence of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists generic labels. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective\_time). Generic fondaparinux labels in openFDA were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:16:13Z. Source state: Current. Version fingerprint: 1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective\_time). Generic fondaparinux labels in openFDA were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE, first bullet. Retrieved 2026-11-09T13:16:13Z. Source state: Current. Version fingerprint: 1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9.
     How it applies: Label passage quoted in the research quote table (LB-05).
  3. Supports: openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective\_time). Generic fondaparinux labels in openFDA were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE, second bullet. Retrieved 2026-11-09T13:16:13Z. Source state: Current. Version fingerprint: 1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9.
     How it applies: Label passage quoted in the research quote table (LB-06).
  4. Supports: openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective\_time). Generic fondaparinux labels in openFDA were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], sentence 1. Retrieved 2026-11-09T13:16:13Z. Source state: Current. Version fingerprint: 1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9.
     How it applies: Label passage quoted in the research quote table (LB-08).
  5. Background: openFDA drug label record for ARIXTRA (fondaparinux sodium injection), Mylan Institutional LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id d3b30c68-cf45-4b46-8ba6-72090f7ba01a (manufacturer Mylan Institutional LLC, application NDA021345), returned on 2026-11-09. The label text is dated 2024-12-10 (effective\_time). Generic fondaparinux labels in openFDA were not read.) <https://api.fda.gov/drug/label.json?search=set_id:%22d3b30c68-cf45-4b46-8ba6-72090f7ba01a%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:16:13Z. Source state: Current. Version fingerprint: 1d611e63e7dc848809fdf4a1b4ee69b259ec37d0d57098327d2bcfd72058bcf9.
     How it applies: Effective date of the label text read, 20241210.

## Connected pages

- The label describes fondaparinux as a Factor Xa inhibitor (anticoagulant); RxClass lists the Factor Xa Inhibitor pharmacologic class: Anticoagulants (`cardio:anticoagulants`)
- FDA label lists prophylaxis and treatment of deep vein thrombosis in adults as an indication: Deep vein thrombosis (`cardio:deep-vein-thrombosis`) [a claim, not a settled fact; see claim `cardio:claim-fda-fondaparinux-label-indications` and its context]
- FDA label lists treatment of acute pulmonary embolism in adults, with warfarin sodium, as an indication: Pulmonary embolism (`cardio:pulmonary-embolism`) [a claim, not a settled fact; see claim `cardio:claim-fda-fondaparinux-label-indications` and its context]
- FDA label lists treatment of venous thromboembolism in pediatric patients aged 1 year or older weighing at least 10 kg as an indication: Venous thromboembolism (`core:venous-thromboembolism`) [a claim, not a settled fact; see claim `cardio:claim-fda-fondaparinux-label-paediatric` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)
- Related to: Superficial vein thrombosis (`cardio:superficial-vein-thrombosis`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 1 registry product

## Provenance

Content hash: 18bb54ee39999d7b46238c5b0a04418e7ee8fd56fc78729e38a295662f0e2d15
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
